Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
Fraiser Kansteiner
Jun 6, 2026 3:28pm
Fierce Pharma
Lilly, Boehringer slash investment plans in Germany
Jun 3, 2026 3:10pm
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B
Jun 3, 2026 7:00am
Lilly locks in vague, 5-program pact with Haisco worth up to $3B
Jun 1, 2026 7:26am
Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome
Jun 1, 2026 3:52am
ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data
May 31, 2026 8:00am